News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Allstate (ALL) came out with quarterly earnings of $8.99 per share, beating the Zacks Consensus Estimate of $5.76 per share. This compares to earnings of $5.94 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +29.8%Allstate (NYSE:ALL) Reports Bullish Q2 CY2026 Insurance giant Allstate (NYSE:ALL) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 10.8% year on year to $18.6 billion. Its non-GAAP profit of $8.99 per share was 48% above analysts' consensus estimates. Is …
Sharemaestro market context Trend signal active 52 weeks +29.8%NORTHBROOK, Ill., Aug. 5, 2026 /PRNewswire/ -- The Allstate Corporation (NYSE: ALL) today reported financial results for the second quarter of 2026.Allstate logo. (PRNewsFoto/Allstate Insurance Company) (PRNewsFoto/) "Allstate delivered strong operating and financial results in the second quarter of 2026, while executing our strategic …
Sharemaestro market context Trend signal active 52 weeks +29.8%Lisata Therapeutics has filed a lawsuit against Kuva Labs Inc. and its subsidiary in Delaware, seeking damages and a $2 million termination fee following the termination of their merger agreement. Concurrently, Lisata has reduced its workforce by approximately 72% to cut operating expenses and …
Lisata Therapeutics (LSTA) has initiated legal proceedings against Kuva Labs and its subsidiary following the termination of their merger agreement, seeking a $2 million termination fee and damages for shareholders. Concurrently, Lisata is exploring strategic alternatives, including potential sales or liquidation, and has significantly …
Lisata Therapeutics, Inc. (LSTA) has filed an 8-K report detailing a major workforce reduction of approximately 72% as part of a cost-cutting initiative to explore strategic options. The company also announced legal action against Kuva Labs Inc. for an alleged breach of a merger …
Partnership builds on more than 20 years of supporting college athletics and expands Allstate's commitment to all sports and all athletes from communities across America Allstate to partner with NBCUniversal to support its multi-platform coverage of the Los Angeles 2028 Olympic and Paralympic Games …
Sharemaestro market context Trend signal active 52 weeks +29.8%Lisata Therapeutics has filed a lawsuit against Kuva Labs in the Delaware Court of Chancery following the termination of their merger agreement, alleging a breach of contract and seeking damages and a $2 million termination fee. The company is also actively evaluating strategic alternatives …
Lisata Therapeutics announced the termination of its merger agreement with Kuva Labs Inc., prompting the company to file a lawsuit against Kuva for breach of contract and seeking a $2 million termination fee. In response to the termination and to conserve cash while exploring …
Globalstar Inc (GSAT) is expected to report a loss of 7 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.
Globalstar (NASDAQ:GSAT) reached a new 52-week high of $84.85, trading up from its previous close of $83.38. Despite this stock performance, analysts generally maintain a "Hold" rating with an average price target below the current share price, and the company recently missed its quarterly …
Globalstar Inc. (GSAT) stock has reached a new 52-week high of $84.68 USD, marking a significant 260% increase over the past year. Despite this strong performance, InvestingPro analysis suggests the stock might be overvalued. The company recently postponed a satellite launch with SpaceX and …
Arrowstreet Capital Limited Partnership reduced its holdings in Globalstar, Inc. by 36.1% in the first quarter, selling 48,344 shares but retaining 85,506 shares valued at $5.68 million. Despite a 16.7% year-over-year revenue increase to $70.06 million, Globalstar missed earnings estimates significantly, reporting a loss …
In the lead-up to Allstate's recent earnings release, investors focused on forecasts calling for lower quarterly earnings than a year earlier alongside higher revenue, with analysts expecting growth in Property-Liability Net Investment Income, Net Premiums Earned, and shifts in auto and homeowners loss and …
Sharemaestro market context Trend signal active 52 weeks +29.8%Globalstar (GSAT) has seen significant share price returns over the last few years, but its current valuation, particularly on a P/S basis, suggests it is expensive compared to industry averages and the Simply Wall St model's fair value. The article highlights a wide gap …
Globalstar Inc (GSAT) has a robust financial status with a current financial score of 7.17, ranking 30 out of 54 in the Telecommunications Services industry. The company reported a 16.71% year-over-year increase in its latest quarterly revenue, reaching $70.06 million, and a 0.45% year-over-year …
The upcoming report from Allstate (ALL) is expected to reveal quarterly earnings of $5.76 per share, indicating a decline of 3% compared to the year-ago period. Analysts forecast revenues of $17.73 billion, representing an increase of 5.7% year over year. Over the last 30 …
Sharemaestro market context Trend signal active 52 weeks +29.8%Allstate Corp (ALL) shares dropped 3.3% to $265.38. The stock is considered significantly overvalued by GuruFocus's GF Value™ at 34.2% above its estimated fair value of $197.73, despite its current P/E ratio of 5.8x being below its 5-year median. The GF Score™ of 67/100 …
Sharemaestro market context Trend signal active 52 weeks +21.3%Bank of America Corp DE significantly increased its stake in The Allstate Corporation (NYSE: ALL) by 8.1% in the first quarter, now holding 7.91 million shares valued at about $1.64 billion. This move contributes to institutional investors collectively owning 76.47% of Allstate. Analysts generally …
This article provides a comprehensive stock analysis of Lisata Therapeutics Inc (LSTA), highlighting its relatively healthy fundamentals, significant growth potential, and high institutional ownership. Despite a recent weak market performance, the company shows strong underlying metrics. The stock is currently deemed fairly valued within …
Allstate (ALL) ended the recent trading session at $265.38, demonstrating a -3.28% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.66%. Elsewhere, the Dow saw an upswing of 1.19%, while the tech-heavy Nasdaq …
Sharemaestro market context Trend signal active 52 weeks +29.8%Globalstar, Inc. (NASDAQ:GSAT) has received a consensus "Hold" recommendation from analysts, with four out of six analysts suggesting a hold and two recommending a buy. The average 12-month price target is set at $69.00, which is below the stock's recent trading price of $79.84. …
Allstate (ALL) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this insurer have returned …
Sharemaestro market context Trend signal active 52 weeks +29.8%This article provides a risk assessment for Globalstar Inc (GSAT), detailing its current risk score, industry ranking, and beta value. It also presents various financial metrics related to volatility, maximum drawdown, return, and liquidity, along with Sharpe Ratio and Skewness data. The assessment indicates …
Globalstar Inc. is set to announce its second-quarter earnings, with analysts anticipating a narrowed loss per share and increased revenue. Investors will focus on the company's ability to demonstrate sustainable revenue acceleration, its path to profitability, and updates regarding Amazon's pending acquisition of the …
The market expects Allstate (ALL) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence …
Sharemaestro market context Trend signal active 52 weeks +29.8%This article provides a valuation analysis of Globalstar Inc (GSAT), detailing its current valuation score, P/E ratio, and market capitalization. It highlights that the company's valuation score is 8.94, ranking it 13th in the Telecommunications Services industry. The P/E, P/B, P/S, and P/CF relevant …
This article analyzes the financial health of Lisata Therapeutics Inc (LSTA), assigning it a TradingKey financial score of 6.89, ranking it 188 out of 385 in the Biotechnology & Medical Research industry. While the company's financial status is described as robust, its operating efficiency …
Kuva Labs (via its subsidiary Kuva Acquisition Corp.) has terminated its tender offer to acquire Lisata Therapeutics (LSTA) due to an inability to secure the necessary financing. The offer, which included $4.00 cash per share plus one contingent value right (CVR) for up to …
Lisata Therapeutics, Inc. (MUN:8NE) generated 85.14K EUR in revenue last year. The top-performing segment was Certepetide, contributing 144.74K EUR, significantly down from 965.98K EUR the previous year. The United States was the largest regional contributor, also at 144.74K EUR, compared to 965.98K EUR in …
Search by ticker symbol or company name and select a result to open its chart.